These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 32416251)
21. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Burnette SE; Poehlein E; Lee HJ; Force J; Westbrook K; Moore HN Breast Cancer Res Treat; 2023 Jan; 197(2):369-376. PubMed ID: 36409396 [TBL] [Abstract][Full Text] [Related]
22. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience. Sarfraz H; Bari S; Whiting J; Sur M; Mo Q; Armitage M; Costa RLB Oncology; 2024; 102(5):414-424. PubMed ID: 38011835 [TBL] [Abstract][Full Text] [Related]
23. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342 [TBL] [Abstract][Full Text] [Related]
24. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685 [TBL] [Abstract][Full Text] [Related]
25. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331 [TBL] [Abstract][Full Text] [Related]
26. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012 [TBL] [Abstract][Full Text] [Related]
27. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881 [TBL] [Abstract][Full Text] [Related]
28. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez Moreno HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Park YH; Sohn J; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin EC; Grinsted L; Schiavon G; Foxley A; Rugo HS; N Engl J Med; 2023 Jun; 388(22):2058-2070. PubMed ID: 37256976 [TBL] [Abstract][Full Text] [Related]
29. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227 [No Abstract] [Full Text] [Related]
30. Periorbital edema associated with alpelisib. Dao EA; George SJ; Heberton MM; Pacha O; Kovitz CA; Patel AB; Phillips RM Cancer Treat Res Commun; 2022; 32():100596. PubMed ID: 35834907 [TBL] [Abstract][Full Text] [Related]
31. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714 [TBL] [Abstract][Full Text] [Related]
32. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Lu YS; Lee KS; Chao TY; Tseng LM; Chitapanarux I; Chen SC; Liu CT; Sohn J; Kim JH; Chang YC; Yang Y; Shotelersuk K; Jung KH; Valenti R; Slader C; Gao M; Park YH Clin Cancer Res; 2021 Jan; 27(2):408-417. PubMed ID: 32718997 [TBL] [Abstract][Full Text] [Related]
33. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. Shen S; Chen Y; Carpio A; Chang C; Iyengar NM Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730 [TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Pharmacodynamic of Alpelisib. Royer B; Kaderbhaï CG; Schmitt A Clin Pharmacokinet; 2023 Jan; 62(1):45-53. PubMed ID: 36633813 [TBL] [Abstract][Full Text] [Related]
36. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001 [TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002 [TBL] [Abstract][Full Text] [Related]
38. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741 [TBL] [Abstract][Full Text] [Related]
39. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084 [TBL] [Abstract][Full Text] [Related]
40. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]